210 related articles for article (PubMed ID: 20661409)
1. Suppressed expression of type 2 3alpha/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) in endometrial hyperplasia and carcinoma.
Zakharov V; Lin HK; Azzarello J; McMeekin S; Moore KN; Penning TM; Fung KM
Int J Clin Exp Pathol; 2010 Jul; 3(6):608-17. PubMed ID: 20661409
[TBL] [Abstract][Full Text] [Related]
2. Aldo-keto reductase family 1 member C3 (AKR1C3) is expressed in adenocarcinoma and squamous cell carcinoma but not small cell carcinoma.
Miller VL; Lin HK; Murugan P; Fan M; Penning TM; Brame LS; Yang Q; Fung KM
Int J Clin Exp Pathol; 2012; 5(4):278-89. PubMed ID: 22670171
[TBL] [Abstract][Full Text] [Related]
3. Differential expression of type 2 3α/type 5 17β-hydroxysteroid dehydrogenase (AKR1C3) in tumors of the central nervous system.
Park AL; Lin HK; Yang Q; Sing CW; Fan M; Mapstone TB; Gross NL; Gumerlock MK; Martin MD; Rabb CH; Fung KM
Int J Clin Exp Pathol; 2010 Mar; 3(8):743-54. PubMed ID: 21151387
[TBL] [Abstract][Full Text] [Related]
4. Increased expression of type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) and its relationship with androgen receptor in prostate carcinoma.
Fung KM; Samara EN; Wong C; Metwalli A; Krlin R; Bane B; Liu CZ; Yang JT; Pitha JV; Culkin DJ; Kropp BP; Penning TM; Lin HK
Endocr Relat Cancer; 2006 Mar; 13(1):169-80. PubMed ID: 16601286
[TBL] [Abstract][Full Text] [Related]
5. Expression of aldo-keto reductase family 1 member C3 (AKR1C3) in neuroendocrine tumors & adenocarcinomas of pancreas, gastrointestinal tract, and lung.
Chang TS; Lin HK; Rogers KA; Brame LS; Yeh MM; Yang Q; Fung KM
Int J Clin Exp Pathol; 2013; 6(11):2419-29. PubMed ID: 24228104
[TBL] [Abstract][Full Text] [Related]
6. Aldo-keto reductases AKR1C1, AKR1C2 and AKR1C3 may enhance progesterone metabolism in ovarian endometriosis.
Hevir N; Vouk K; Sinkovec J; Ribič-Pucelj M; Rižner TL
Chem Biol Interact; 2011 May; 191(1-3):217-26. PubMed ID: 21232532
[TBL] [Abstract][Full Text] [Related]
7. AKR1C1 and AKR1C3 may determine progesterone and estrogen ratios in endometrial cancer.
Rizner TL; Smuc T; Rupreht R; Sinkovec J; Penning TM
Mol Cell Endocrinol; 2006 Mar; 248(1-2):126-35. PubMed ID: 16338060
[TBL] [Abstract][Full Text] [Related]
8. Aldo-keto reductase 1C3 expression in MCF-7 cells reveals roles in steroid hormone and prostaglandin metabolism that may explain its over-expression in breast cancer.
Byrns MC; Duan L; Lee SH; Blair IA; Penning TM
J Steroid Biochem Mol Biol; 2010 Feb; 118(3):177-87. PubMed ID: 20036328
[TBL] [Abstract][Full Text] [Related]
9. Expression of AKR1C3 in renal cell carcinoma, papillary urothelial carcinoma, and Wilms' tumor.
Azzarello JT; Lin HK; Gherezghiher A; Zakharov V; Yu Z; Kropp BP; Culkin DJ; Penning TM; Fung KM
Int J Clin Exp Pathol; 2009 Nov; 3(2):147-55. PubMed ID: 20126582
[TBL] [Abstract][Full Text] [Related]
10. Characterization of a monoclonal antibody for human aldo-keto reductase AKR1C3 (type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase); immunohistochemical detection in breast and prostate.
Lin HK; Steckelbroeck S; Fung KM; Jones AN; Penning TM
Steroids; 2004 Dec; 69(13-14):795-801. PubMed ID: 15582534
[TBL] [Abstract][Full Text] [Related]
11. AKR1C3 overexpression may serve as a promising biomarker for prostate cancer progression.
Tian Y; Zhao L; Zhang H; Liu X; Zhao L; Zhao X; Li Y; Li J
Diagn Pathol; 2014 Feb; 9():42. PubMed ID: 24571686
[TBL] [Abstract][Full Text] [Related]
12. The analyses of 17beta-hydroxysteroid dehydrogenase isozymes in human endometrial hyperplasia and carcinoma.
Utsunomiya H; Suzuki T; Kaneko C; Takeyama J; Nakamura J; Kimura K; Yoshihama M; Harada N; Ito K; Konno R; Sato S; Okamura K; Sasano H
J Clin Endocrinol Metab; 2001 Jul; 86(7):3436-43. PubMed ID: 11443221
[TBL] [Abstract][Full Text] [Related]
13. Expression of hyaluronic acid and its receptors, CD44s and CD44v6, in normal, hyperplastic, and neoplastic endometrium.
Afify AM; Craig S; Paulino AF; Stern R
Ann Diagn Pathol; 2005 Dec; 9(6):312-8. PubMed ID: 16308159
[TBL] [Abstract][Full Text] [Related]
14. Expression of progesterone metabolizing enzyme genes (AKR1C1, AKR1C2, AKR1C3, SRD5A1, SRD5A2) is altered in human breast carcinoma.
Lewis MJ; Wiebe JP; Heathcote JG
BMC Cancer; 2004 Jun; 4():27. PubMed ID: 15212687
[TBL] [Abstract][Full Text] [Related]
15. An indomethacin analogue, N-(4-chlorobenzoyl)-melatonin, is a selective inhibitor of aldo-keto reductase 1C3 (type 2 3alpha-HSD, type 5 17beta-HSD, and prostaglandin F synthase), a potential target for the treatment of hormone dependent and hormone independent malignancies.
Byrns MC; Steckelbroeck S; Penning TM
Biochem Pharmacol; 2008 Jan; 75(2):484-93. PubMed ID: 17950253
[TBL] [Abstract][Full Text] [Related]
16. Human 3alpha-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones.
Penning TM; Burczynski ME; Jez JM; Hung CF; Lin HK; Ma H; Moore M; Palackal N; Ratnam K
Biochem J; 2000 Oct; 351(Pt 1):67-77. PubMed ID: 10998348
[TBL] [Abstract][Full Text] [Related]
17. Retinoid receptors in the human endometrium and its disorders: a possible modulator of 17 beta-hydroxysteroid dehydrogenase.
Ito K; Suzuki T; Moriya T; Utsunomiya H; Sugawara A; Konno R; Sato S; Sasano H
J Clin Endocrinol Metab; 2001 Jun; 86(6):2721-7. PubMed ID: 11397877
[TBL] [Abstract][Full Text] [Related]
18. Altered expression of genes involved in progesterone biosynthesis, metabolism and action in endometrial cancer.
Sinreih M; Hevir N; Rižner TL
Chem Biol Interact; 2013 Feb; 202(1-3):210-7. PubMed ID: 23200943
[TBL] [Abstract][Full Text] [Related]
19. Variation in AKR1C3, which encodes the neuroactive steroid synthetic enzyme 3α-HSD type 2 (17β-HSD type 5), moderates the subjective effects of alcohol.
Milivojevic V; Feinn R; Kranzler HR; Covault J
Psychopharmacology (Berl); 2014 Sep; 231(17):3597-608. PubMed ID: 24838369
[TBL] [Abstract][Full Text] [Related]
20. Identification of a novel estrogen-regulated gene, EIG121, induced by hormone replacement therapy and differentially expressed in type I and type II endometrial cancer.
Deng L; Broaddus RR; McCampbell A; Shipley GL; Loose DS; Stancel GM; Pickar JH; Davies PJ
Clin Cancer Res; 2005 Dec; 11(23):8258-64. PubMed ID: 16322283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
